Whenever the cancer treatment continues or to stop it, the potential risk of cancer progression in the patients is very controversial, hence the oncological society may be recommended as the cancer patient should continue and complete their conventional treatment despite the risk of infection. If the diagnosis and treatment of malignancy (advance stage) will be a delay which results depreciated the performance, admission for symptom palliation, and progressive growth of cancer. Before the generalization of any type of recommendation, clinical trials must be needed for cancer patients with COVID-19 disease. Cancer patients with Early stages are likely less susceptible to SARC-Co-V 2 infection compared to advance stages. Therefore, delaying the some treatment of some cancer (like as breast, prostate, cervical) with early stages might be an option for avoiding COVID infection, but patients with solid tumors such as lung & pancreatic cancer and hematological cancer such as acute leukemia, and lymphoma should take the treatment and diagnostic measurements on timely in order to decrease the mortality. During the COVID-19 outbreak, Kutikov et al., have offered the specific recommendations which can be used to monitor the decision making on continuing or delaying anti-cancer treatment.